Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

How Pfizer vaccine could be cold comfort for some Asian nations

Published 10/11/2020, 10:03 pm
Updated 10/11/2020, 10:06 pm
© Reuters.

By Rocky Swift, Sangmi Cha and Neil Jerome Morales

TOKYO/SEOUL/MANILA, Nov 10 (Reuters) - With tropical heat, remote island communities and a dearth of ultra-cold freezers, many Asian countries aren't betting on Pfizer 's experimental vaccine solving their COVID-19 crisis any time soon.

The world cheered on Monday when Pfizer Inc (NYSE:PFE) PFE.N announced its shot, jointly developed with BioNTech SE BNTX.O , was more than 90% effective based on initial trial results. health experts cautioned that the vaccine, should it be approved, was no silver bullet - not least because the genetic material it's made from needs to be stored at temperatures of minus 70 degrees Celsius (-94 F) or below.

Such requirements pose a particularly daunting challenge for countries in Asia, as well as in places like Africa and Latin America, where intense heat is often compounded by poor infrastructure that will make it difficult to keep the "cold chain" intact during deliveries to rural areas and islands.

That is a problem for everyone in the world, given the World Health Organization estimates about 70% of people must be inoculated to end the pandemic, and Asia alone is home to more than 4.6 billion - or three-fifths of the global population.

Some Asian countries are prioritising containing the novel coronavirus rather than looking to stockpile vaccines, while others are looking for alternatives to the messenger RNA technology used by Pfizer that requires such ultra-cold storage.

"On the cold chain requirement of -70 degrees, that is a hefty requirement. We do not have such facility," Philippines' Health Secretary Francisco Duque told Reuters.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"We will have to wait and see for now," he added. "The technology Pfizer is using is new technology. We don't have experience with that, so risks can be high."

Pfizer told Reuters that it had developed detailed logistical plans and tools to support vaccine transport, storage and continuous temperature monitoring.

"We have also developed packaging and storage innovations to be fit for purpose for the range of locations where we believe vaccinations will take place," it said.

'VACCINE IS STORY FOR FUTURE'

Yet even wealthier nations like South Korea and Japan are managing expectations.

"Storage is going to be a big challenge for us," said Fumie Sakamoto, infection control manager at St. Luke's International Hospital in Tokyo.

"I'm not sure how well prepared our government is with regards to maintaining the cold chain. Hospitals in Japan usually do not have ultra-cold freezers, but I think it's high time we started thinking about the logistics for the vaccine."

Japan is among three countries in Asia Pacific that have announced supply deals for the Pfizer/BioNTech vaccine. It has signed a deal for 120 million doses, while Australia has secured 10 million doses and China's Fosun 600196.SS has secured 10 million doses for Hong Kong and Macau. PHC Corp, which supplies medical freezers, told Reuters that demand had shot up 150% this year and that they were increasing production to meet demand.

Kwon Jun-wook, an official at South Korea's Disease Control and Prevention Agency (KDCA), said it wanted to see how vaccination progressed in other countries first and would thoroughly review its supply chain.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The country had recently experienced the problems of cold storage when it had to discard about 5 million doses of flu vaccines because they were not stored at recommended temperatures. 2018 study commissioned by the agency found that only a quarter of 2,200 private clinics it surveyed had medical refrigerators, with 40% using household refrigerators.

For some countries, it's still very early days.

Indonesia, whose 273 million people are scattered over more than 17,000 islands, is considering a variety of vaccines, but the Pfizer one is not yet among them, said Airlangga Hartarto, who heads the country's COVID-19 response team.

Vietnam, which successfully contained its outbreak through aggressive mass testing and strict border controls, said it would continue to focus on containment effort. vaccine is a story for the future," Deputy Prime Minister Vu Duc Dam, told a government meeting on Friday.

"Demand is far higher than supply, and we have to pay large deposits to secure our position, which I see as very high risk and a waste of money and time."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.